October 02, 2025

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

Roswell Park Comprehensive Cancer Center

September 29, 2025

Sunburns Linked to Squamous Cell Carcinoma Risk

Childhood severe sunburns carry 3-fold higher cancer risk than adult exposure

Conexiant

September 25, 2025

Utah Study Finds Fewer Melanoma Cases With Tattoos

Tattooed patients show varying melanoma risks by session number.

Conexiant

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 09, 2025

Top 10 States to Practice Dermatology

The following list highlights the states that offer the most favorable conditions for dermatologists.

Conexiant

May 27, 2021

Study Finds Adjuvant Immunotherapy of Benefit to Patients With Stage IIB/C Melanoma

A significant survival advantage accrued to patients with stage IIB and IIC cutaneous melanoma who received adjuvant immunotherapy, a large retrospective cohort study reported at the Society of Surgic...

The ASCO Post

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

April 30, 2024

Study Explores Impact of Cannabis Extract on Melanoma Cells

The cannabis extract cannabinoid PHEC-66 may effectively treat melanoma.

Conexiant

April 30, 2024

Model for Predicting Survival Following SLNB in Melanoma

Researchers have developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.

Conexiant